MedTrace Logo

Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity

NCT02557984 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2015-09-23

No results posted yet for this study

Summary

The purpose of this study is to determine how the dopamine and opioid system is involved in reward processing, specifically in cue-induced reward responding and reward impulsivity, using dopamine and opioid receptor antagonists in healthy participants. The investigators predict that particularly the dopamine challenge should alter cue-induced reward responding and reward impulsivity. Such effects would be of high interest for the treatment of disorders which involve impairments of reward processing such as addiction.

Conditions

Interventions

DRUG

Placebo

Placebo Pill

DRUG

Amisulpride

400 mg Amisulpride

DRUG

Naltrexone

50 mg Naltrexone

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Boris B Quednow, Prof · University Hospital of Psychiatry Zurich

  • Philippe N Tobler, Prof · Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02557984 on ClinicalTrials.gov